A Phase 2 interventional study of LY4395089 and Mirikizumab - Intravenous (IV) in Crohn Disease, sponsored by Eli Lilly and Company. Recruiting at 71 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Crohn Disease by Eli Lilly and Company — 6 open to participants now, 7 under way, 4 of them phase 3. Crohn Disease · Eli Lilly and Company.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 9th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 10 studies in Crohn Disease by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Belgium and 19 more countries
Ages 18–70
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Sites in United States, Australia, Austria and 25 more countries
Ages 18–85
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–17
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 171 across the 10 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
2 of the studies in Crohn Disease by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07483099Eli Lilly and CompanyA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | 2027-06 |
| NCT07483073Eli Lilly and CompanyA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all the inclusion criteria in the IIBD master protocol, except the UC-specific criteria. In addition, they must meet the criteria below:
Exclusion Criteria:
Participants are excluded from the study if any of the exclusion criteria in the IIBD master protocol, except the UC-specific criteria apply, or if any of the following criteria apply:
Must not have had any of the following within the past 180 days before screening:
Study Period 1: Mirikizumab administered via IV. Study Period 2: Responders will receive mirikizumab SC.
Drug: Mirikizumab - Intravenous (IV) · Drug: Mirikizumab - Subcutaneous (SC)
Study Period 1: Co-administration of LY4395089 administered orally and mirikizumab administered IV. Study Period 2: Responders will stop LY4395089 and receive mirikizumab SC.
Drug: LY4395089 · Drug: Mirikizumab - Intravenous (IV) · Drug: Mirikizumab - Subcutaneous (SC)
Administered orally
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response
The percentage of participants who achieve endoscopic response at week 12 of Study Period 1.
Time frame: Baseline, Up to Week 12
Percentage of Participants who Achieve Clinical Remission
Time frame: Baseline, Up to Week 12
Percent Change from Baseline in Fecal Calprotectin
Time frame: Baseline, Up to Week 12
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 13 months is below that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY4395089